These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 20002504)

  • 21. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
    Knight JS; Tsodikov A; Cibrik DM; Ross CW; Kaminski MS; Blayney DW
    J Clin Oncol; 2009 Jul; 27(20):3354-62. PubMed ID: 19451438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management and outcome of liver recipients with post-transplant lymphoproliferative disease.
    Glez-Chamorro A; Jimenez C; Moreno-Glez E; Glez-Pinto I; Loinaz C; Gomez R; Garcia I; Alonso O; Palma F; Grande C
    Hepatogastroenterology; 2000; 47(31):211-9. PubMed ID: 10690611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Late-onset post-transplantation lymphoproliferative disorders after kidney transplantation: a monocentric study over three decades.
    Michonneau D; Suarez F; Lambert J; Adam J; Brousse N; Canioni D; Anglicheau D; Martinez F; Snanoudj R; Legendre C; Hermine O; Mamzer-Bruneel MF
    Nephrol Dial Transplant; 2013 Feb; 28(2):471-8. PubMed ID: 23129824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial.
    Blaes AH; Peterson BA; Bartlett N; Dunn DL; Morrison VA
    Cancer; 2005 Oct; 104(8):1661-7. PubMed ID: 16149091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients.
    Libertiny G; Watson CJ; Gray DW; Welsh KI; Morris PJ
    Br J Surg; 2001 Oct; 88(10):1330-4. PubMed ID: 11578286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience.
    Micallef IN; Chhanabhai M; Gascoyne RD; Shepherd JD; Fung HC; Nantel SH; Toze CL; Klingemann HG; Sutherland HJ; Hogge DE; Nevill TJ; Le A; Barnett MJ
    Bone Marrow Transplant; 1998 Nov; 22(10):981-7. PubMed ID: 9849695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation.
    Maecker B; Jack T; Zimmermann M; Abdul-Khaliq H; Burdelski M; Fuchs A; Hoyer P; Koepf S; Kraemer U; Laube GF; Müller-Wiefel DE; Netz H; Pohl M; Toenshoff B; Wagner HJ; Wallot M; Welte K; Melter M; Offner G; Klein C
    J Clin Oncol; 2007 Nov; 25(31):4902-8. PubMed ID: 17971586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of risk factors for the development of posttransplant lymphoprolipherative disorder among 119 children who received primary intestinal transplants at a single center.
    Quintini C; Kato T; Gaynor JJ; Ueno T; Selvaggi G; Gordon P; McLaughlin G; Tompson J; Ruiz P; Tzakis A
    Transplant Proc; 2006; 38(6):1755-8. PubMed ID: 16908272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamic EBV gene loads in renal, hepatic, and cardiothoracic transplant recipients as determined by real-time PCR light cycler.
    Leung E; Shenton BK; Green K; Jackson G; Gould FK; Yap C; Talbot D
    Transpl Infect Dis; 2004 Dec; 6(4):156-64. PubMed ID: 15762933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-transplant lymphoproliferative disorders after heart or kidney transplantation at a single centre: presentation and response to treatment.
    Aversa SM; Stragliotto S; Marino D; Calabrese F; Rigotti P; Marchini F; Gambino A; Feltrin G; Boso C; Canova F; Soldà C; Mazzarotto R; Burra P
    Acta Haematol; 2008; 120(1):36-46. PubMed ID: 18797163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Post-transplant lymphoproliferative disorder following pediatric heart transplantation.
    Mendoza F; Kunitake H; Laks H; Odim J
    Pediatr Transplant; 2006 Feb; 10(1):60-6. PubMed ID: 16499589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
    Younes BS; McDiarmid SV; Martin MG; Vargas JH; Goss JA; Busuttil RW; Ament ME
    Transplantation; 2000 Jul; 70(1):94-9. PubMed ID: 10919581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients.
    Shahinian VB; Muirhead N; Jevnikar AM; Leckie SH; Khakhar AK; Luke PP; Rizkalla KS; Hollomby DJ; House AA
    Transplantation; 2003 Mar; 75(6):851-6. PubMed ID: 12660514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution.
    Choquet S; Oertel S; LeBlond V; Riess H; Varoqueaux N; Dörken B; Trappe R
    Ann Hematol; 2007 Aug; 86(8):599-607. PubMed ID: 17522862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Posttransplant lymphoproliferative disorders in transplant recipients.
    Timurağaoğlu A; Uğur-Bilgin A; Colak D; Tuncer M; Gölbaşi I; Hazar V; Kiliçarsłan B; Undar L; Demirbaş A
    Transplant Proc; 2006 Mar; 38(2):641-5. PubMed ID: 16549195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation.
    Cherikh WS; Kauffman HM; McBride MA; Maghirang J; Swinnen LJ; Hanto DW
    Transplantation; 2003 Nov; 76(9):1289-93. PubMed ID: 14627905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
    Sundin M; Le Blanc K; Ringdén O; Barkholt L; Omazic B; Lergin C; Levitsky V; Remberger M
    Haematologica; 2006 Aug; 91(8):1059-67. PubMed ID: 16885046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence of post-transplantation lymphoproliferative disease in Andalusia (1990-2009).
    Govantes MA; Esteve AF; Ramos MT; Gracia De Guindo MC; Sánchez LF; Blanca MA; Rodríguez-Benot A; Blandino MV; De la Nuez PC; Rodríguez DB
    Transplant Proc; 2013; 45(10):3592-4. PubMed ID: 24314968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative analysis of post-transplant lymphoproliferative disorder after kidney transplantation versus hematopoietic stem cell transplantation.
    Yoon JH; Lee S; Kim HJ; Lee JW; Min WS; Chung BH; Yang CW; Kim YS; Kim JI; Moon IS; Oh EJ; Park GS; Cho SG
    Transpl Int; 2014 Jul; 27(7):721-32. PubMed ID: 24684689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.